Amneal Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amneal Pharmaceuticals, Inc.
Amneal’s president and co-CEO, Chirag Patel, has shared the company’s long-term plan of becoming one of the top biosimilars players in the US. The company is set to launch three biosimilars this year, while building its manufacturing capabilities and looking for opportunities and partnerships.
Amneal says an $83.5m deal to acquire Saol Therapeutics’ baclofen franchise will also bring the firm an “experienced institutional commercial team” that will be able to support three biosimilar launches that the company now expects to execute in 2022.
The agency offers ‘regulatory flexibility’ for certain requirements of the iPLEDGE REMS for the acne drug if manufacturers address delays in implementing the modified program.
After an extraordinary year that saw demand patterns and the supply chain upended by the COVID-19 pandemic, as well as a major merger that has transformed one of the global off-patent industry’s biggest players, Generics Bulletin’s Top 50 has once again seen significant changes.
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Amedra Pharmaceuticals LLC
- Amneal Pharmaceuticals, LLC
- CorePharma LLC
- Gemini Laboratories, LLC
- Impax Generics
- Impax Laboratories, Inc. (IPXL)
- Impax Specialty Pharma
- Lineage Therapeutics Inc.
- Tower Holdings, Inc.